Eandtnews

Duchenne Muscular Dystrophy Market Size, Share, Trend, Epidemiology & Market Forecast to 2030

 Breaking News
  • No posts were found

Duchenne Muscular Dystrophy Market Size, Share, Trend, Epidemiology & Market Forecast to 2030

March 26
14:40 2020
Duchenne Muscular Dystrophy Market Size, Share, Trend, Epidemiology & Market Forecast to 2030

Delveinsight Business Research
DelveInsight’s “Duchenne Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Duchenne Muscular Dystrophy, historical and forecasted epidemiology as well as the Duchenne Muscular Dystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Duchenne Muscular Dystrophy market report covers emerging drugs, current treatment practices, Duchenne Muscular Dystrophy market share of the individual therapies, current and forecasted Duchenne Muscular Dystrophy Market Size from 2017 to 2030 segmented by seven major markets. 

The report also provides detailed current Duchenne Muscular Dystrophy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. 

 

Duchenne Muscular Dystrophy Market Key Facts

According to NHS UK, around 70,000 people have MD or a related condition in the United Kingdom. DMD is the most common type of MD. In the UK, about 100 boys are born with Duchenne MD each year, and there are about 2,500 people living with the condition in the UK at any one time.

According to the National Organization for Rare Disorders, DMD is the most common childhood-onset form of muscular dystrophy and affects males almost exclusively.

The prevalence is estimated to be 1 in every 3,500 live male births. Age of onset is usually between 3 and 5 years of age. The muscular dystrophies as a whole are estimated to affect 250,000 individuals in the United States.

The total prevalent population of DMD in seven major markets was found to be 31,386 in 2017.

 

Visit For Sample Pages: 

https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market

 

Key Benefits of Duchenne Muscular Dystrophy Market Report

Duchenne Muscular Dystrophy market report provides an in-depth analysis of Duchenne Muscular Dystrophy Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.

The Duchenne Muscular Dystrophy market report will help in developing business strategies by understanding the Duchenne Muscular Dystrophy Market trends & developments, key players and future market competition that will shape and drive the Duchenne Muscular Dystrophy market in the upcoming years.

The Duchenne Muscular Dystrophy market report covers Duchenne Muscular Dystrophy current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

The report provides a detailed assessment of the Duchenne Muscular Dystrophy market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

 

Duchenne Muscular Dystrophy Market

The Duchenne Muscular Dystrophy market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Duchenne Muscular Dystrophy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 

 The report gives a thorough detail of Duchenne Muscular Dystrophy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. 

 

Duchenne Muscular Dystrophy Epidemiology

The Duchenne Muscular Dystrophy epidemiology section covers insights about historical and current Duchenne Muscular Dystrophy patient pool and forecasted trend for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

 

Duchenne Muscular Dystrophy Drugs Uptake and Key Market Players

Duchenne Muscular Dystrophy Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Duchenne Muscular Dystrophy market or expected to get launched in the market during the study period. The analysis covers Duchenne Muscular Dystrophy market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Some of the key players in Duchenne Muscular Dystrophy market include Italfarmaco, Catabasis Pharmaceuticals, Santhera Pharmaceuticals, Hoffmann-La Roche, FibroGen, Capricor and others.

Edasalonexent (CAT-1004), Givinostat,  Idebenone, RG6206 (BMS-986089), Pamrevlumab, CAP-1002, are some of the emerging therapies in Duchenne Muscular Dystrophy market.

 

Table of Contents

1. Key Insights

2. Executive Summary 

3. Duchenne Muscular Dystrophy Competitive Intelligence Analysis

4. Duchenne Muscular Dystrophy Market Overview at a Glance

5. Duchenne Muscular Dystrophy Disease Background and Overview

6. Duchenne Muscular Dystrophy Patient Journey

7. Duchenne Muscular Dystrophy Epidemiology and Patient Population

8. Duchenne Muscular Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices

9. Duchenne Muscular Dystrophy Unmet Needs

10. Key Endpoints of Duchenne Muscular Dystrophy Treatment

11. Duchenne Muscular Dystrophy Marketed Products

12. Duchenne Muscular Dystrophy Emerging Therapies

13. Duchenne Muscular Dystrophy Seven Major Market Analysis

14. Attribute Analysis

15. Duchenne Muscular Dystrophy Market Outlook (7 major markets)

16. Duchenne Muscular Dystrophy Access and Reimbursement Overview

17. KOL Views on the Duchenne Muscular Dystrophy Market.

18. Duchenne Muscular Dystrophy Market Drivers

19. Duchenne Muscular Dystrophy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/